Janssen Of Japan To Develop ER Painkiller Patch Solely For Japan
This article was originally published in PharmAsia News
Japan's Janssen Pharmaceutical, a subsidiary of U.S.-based Johnson & Johnson, has applied to develop an extended-release painkiller developed for the Japanese market. Janssen's Durotep (fentanyl) is a one-day analgesic patch, which the firm hopes to be able to begin marketing next year. The patch is available as a three-day treatment, but patients complained they needed to change the patch so they could bathe daily. Janssen used the technology of a J&J joint venture with biotech Alza to develop an extended-release version. (Click here for more - a subscription may be required
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.